Eric Therrien

List of Publications by Year
in descending order

32	1,159	361296 20	434063 31
papers	citations	h-index	g-index

35	35	35	1652
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An Allosteric Inhibitory Site Conserved in the Ectodomain of P2X Receptor Channels. Frontiers in Cellular Neuroscience, 2019, 13, 121.	1.8	23
2	An allosteric mechanism for potent inhibition of human ATP-citrate lyase. Nature, 2019, 568, 566-570.	13.7	105
3	Medicinal Chemistry Projects Requiring Imaginative Structure-Based Drug Design Methods. Accounts of Chemical Research, 2016, 49, 1646-1657.	7.6	40
4	Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2527-2531.	1.0	17
5	Design, synthesis and RON receptor tyrosine kinase inhibitory activity of new head groups analogs of LCRF-0004. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3810-3815.	1.0	13
6	Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3706-3710.	1.0	11
7	Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2514-2518.	1.0	25
8	Docking Ligands into Flexible and Solvated Macromolecules. 7. Impact of Protein Flexibility and Water Molecules on Docking-Based Virtual Screening Accuracy. Journal of Chemical Information and Modeling, 2014, 54, 3198-3210.	2.5	27
9	Docking Ligands into Flexible and Solvated Macromolecules. 6. Development and Application to the Docking of HDACs and other Zinc Metalloenzymes Inhibitors. Journal of Chemical Information and Modeling, 2014, 54, 254-265.	2.5	39
10	Methods for Docking Small Molecules to Macromolecules: A Userâ€™s Perspective. 1. The Theory. Current Pharmaceutical Design, 2014, 20, 3338-3359.	0.9	20
11	Methods for Docking Small Molecules to Macromolecules: A Userâ€™s Perspective. 2. Applications. Current Pharmaceutical Design, 2014, 20, 3360-3372.	0.9	8
12	Integrating Medicinal Chemistry, Organic/Combinatorial Chemistry, and Computational Chemistry for the Discovery of Selective Estrogen Receptor Modulators with F<scp>orecaster</scp>, a Novel Platform for Drug Discovery. Journal of Chemical Information and Modeling, 2012, 52, 210-224.	2.5	39
13	Development of a Computational Tool to Rival Experts in the Prediction of Sites of Metabolism of Xenobiotics by P450s. Journal of Chemical Information and Modeling, 2012, 52, 2471-2483.	2.5	52
14	Virtual Screening and Computational Optimization for the Discovery of Covalent Prolyl Oligopeptidase Inhibitors with Activity in Human Cells. Journal of Medicinal Chemistry, 2012, 55, 6306-6315.	2.9	47
15	Modeling Reality for Optimal Docking of Small Molecules to Biological Targets. Current Computer-Aided Drug Design, 2009, 5, 241-263.	0.8	13
16	Sulfamides as novel histone deacetylase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 336-340.	1.0	32
17	N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1218-1223.	1.0	84
18	Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1866-1870.	1.0	19

#	Article	IF	Citations
19	From natural products to achiral drug prototypes: Potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5429-5432.	1.0	11
20	1,2-Diamines as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6725-6732.	1.0	47
21	Design, synthesis, and thrombin-inhibitory activity of pyridin-2-ones as P2/P3 core motifs. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1972-1976.	1.0	26
22	A Method for Induced-Fit Docking, Scoring, and Ranking of Flexible Ligands. Application to Peptidic and Pseudopeptidic Î²-secretase (BACE 1) Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 5885-5894.	2.9	60
23	Phenolic P2/P3 core motif as thrombin inhibitorsâ€"Design, synthesis, and X-ray co-crystal structure. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1032-1036.	1.0	18
24	Synthetic Approaches to Polyhydroxy Indolizidines and Related Azabicyclic Scaffolds. Heterocycles, 2006, 70, 461.	0.4	14
25	Structure-Based Design, Synthesis, and Memapsin 2 (BACE) Inhibitory Activity of Carbocyclic and Heterocyclic Peptidomimetics. Journal of Medicinal Chemistry, 2005, 48, 5175-5190.	2.9	74
26	Synthesis of 310-Helix-Inducing Constrained Analogues ofl-Proline. Journal of Organic Chemistry, 2004, 69, 4891-4899.	1.7	29
27	Targeting Thrombin and Factor VIIa: Design, Synthesis, and Inhibitory Activity of Functionally Relevant Indolizidinones.. ChemInform, 2003, 34, no.	0.1	0
28	Synthesis of functionally diverse bicyclic sulfonamides as constrained proline analogues and application to the design of potential thrombin inhibitors. Tetrahedron, 2003, 59, 7047-7056.	1.0	92
29	Synthesis of Diversely Functionalized Indolizidinones and Related Bicyclic Lactams Using Intramolecular Grubbs Olefin Metathesis and Dieckmann Condensation. Journal of Organic Chemistry, 2003, 68, 7219-7233.	1.7	60
30	Targeting thrombin and factor VIIa: design, synthesis, and inhibitory activity of functionally relevant indolizidinones. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2907-2911.	1.0	56
31	Peptide coupling of unprotected amino acids through in situ p-nitrophenyl ester formation. Tetrahedron Letters, 2002, 43, 7717-7719.	0.7	31
32	A comparative docking study and the design of potentially selective MMP inhibitors. Journal of Computer-Aided Molecular Design, 2001, 15, 873-881.	1.3	27